BIOMARKER:

NF1 mutation

B | Sensitive

C2 | Sensitive

C3 | Sensitive

C4 | Sensitive

D | Sensitive

B | Resistant

C2 | Resistant

C3 | Resistant

C4 | Resistant

D | Resistant

Melanoma

Glioblastoma

Glioma

CNS Tumor

Thyroid Gland Anaplastic Carcinoma

Colorectal Cancer

Multiple Myeloma

Thyroid Gland Medullary Carcinoma

Sarcoma

Lung Cancer

Soft Tissue Sarcoma

Solid Tumor

Neurofibrosarcoma

Breast Cancer

Non Small Cell Lung Cancer

bevacizumab

NF1 mutation|Glioblastoma|bevacizumab

trametinib

NF1 mutation|Glioblastoma|trametinib

NF1 mutation|Glioma|trametinib

NF1 mutation|Lung Cancer|trametinib

atezolizumab + cobimetinib

NF1 mutation|Thyroid Gland Anaplastic Carcinoma|atezolizumab + cobimetinib

AZD6738

NF1 mutation|Colorectal Cancer|AZD6738

FCN-159

NF1 mutation|Glioma|FCN-159

selumetinib

NF1 mutation|CNS Tumor|selumetinib

NF1 mutation|Solid Tumor|selumetinib

RMC-4630

NF1 mutation|Sarcoma|RMC-4630

vandetanib

NF1 mutation|Thyroid Gland Medullary Carcinoma|vandetanib

vemurafenib

NF1 mutation|Melanoma|vemurafenib

ifosfamide + pegylated liposomal doxorubicin

NF1 mutation|Soft Tissue Sarcoma|ifosfamide + pegylated liposomal doxorubicin

cobimetinib

NF1 mutation|Melanoma|cobimetinib

VTX-11e

NF1 mutation|Melanoma|VTX-11e

PD-0325901

NF1 mutation|Melanoma|PD-0325901

DR6MP + JHU395

NF1 mutation|Neurofibrosarcoma|DR6MP + JHU395

DR6MP

NF1 mutation|Neurofibrosarcoma|DR6MP

ERAS-601

NF1 mutation|Non Small Cell Lung Cancer|ERAS-601

CDK4 inhibitor + CDK6 inhibitor

NF1 mutation|Breast Cancer|CDK4 inhibitor + CDK6 inhibitor

PD1 inhibitor + MEK inhibitor

NF1 mutation|Melanoma|PD1 inhibitor + MEK inhibitor

Immunotherapy

NF1 mutation|Melanoma|Immunotherapy

MEK inhibitor

NF1 mutation|Multiple Myeloma|MEK inhibitor

MEK inhibitor + c-MET inhibitor

NF1 mutation|Neurofibrosarcoma|MEK inhibitor + c-MET inhibitor